CohBar Inc

Change company Symbol lookup

Select an option...

CWBR CohBar Inc

PEP PepsiCo Inc

AGNC Agnc Investment Corp

ACM AECOM

CLSN Celsion Corp

BAC Bank of America Corp

GPHBF Graphene 3D Lab Inc(British Columbia)

ITRI Itron Inc

LTTTX MFS Lifetime 2025 Fund Class R3

HLI Houlihan Lokey Inc

Go

CohBar, Inc. (CohBar), is a clinical stage biotechnology company. The Company is focused on the research and development of mitochondria-based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The Company has discovered more than 100 mitochondrial-derived peptides and is focused on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases, including nonalcoholic steatohepatitis (NASH), obesity, cancer, fibrotic diseases including idiopathic pulmonary fibrosis (IPF), type 2 diabetes (T2D), cardiovascular and neurodegenerative diseases. The Company’s lead compound, CB4211, is in the phase 1b stage of a phase 1a/1b clinical trial for NASH and obesity. In addition, CohBar has four preclinical programs that include MBT5 Analogs (CXCR4 Antagonists) for Cancer and Other Disease Indicatio, MBT2 Analogs for Fibrotic Diseases, MBT3 Analog for Cancer Immunotherapy and CB5064 Analogs for Type 2 Diabetes.